Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
- 19 Sep 2022 Results of post-hoc analysis of two studies (TEMSO; NCT00134563 & long-term extension NCT00803049) assessing relationship between teriflunomide's effects on brain volume loss and cognition, published in the Multiple Sclerosis Journal.
- 09 Jun 2019 Trial has been completed in UK.
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis